BioMarin Pharmaceutical Inc (BMRN) valuation history

$55.95

Latest weekly close · Market cap $10.9B

Share BMRN EV/Sales history
Below its usual range

As of

BMRN's EV/Sales of 4.2x is lower than 72% of its weekly readings over the last five years.

Weekly EV/Sales with its 5-year range

EV/Sales each weekMiddle half of the last 5 years5-year median 6.6×
EV/Sales weekly history0×2.5×5×7.5×10×12.5×4.2×20222023202420252026
5-year median
6.6×
10-year median
8.1×
5-year low to high
2.9×–10.7×
Versus 5-year median
-37%

EV/Sales

28thpercentile

of its weekly readings over the last five years

Below its usual range

Growth, last 12 months vs the year before

Revenue
+11%slowing
EPS
-89%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading
-2,00002,0004,0006,00020222023202420252026

EV/Sales at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

BMRN EV/Sales at each year-end
Year-endEV/Sales5-year percentile
3.4×6
4.7×3
7.8×21
9.5×63
8.8×36
9.1×17
9.8×12
n/aToo little history
12.4×5
12.9×24

Loading peers and related research…

About this history

What is BMRN's current EV/Sales?
BMRN's EV/Sales of 4.2x is lower than 72% of its weekly readings over the last five years.
What is BMRN's five-year median EV/Sales?
6.6x. Half of BMRN's weekly readings over the last five years were higher and half were lower. This page has 809 weekly readings, from Apr 25, 2011 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?
No. The rank compares BMRN only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Source: SEC company filings and weekly market prices. Multiples use the last twelve months of financial results. Updated .

How the valuation data is built